- Home
- BTGO vs ARVN Comparison
BTGO vs ARVN Comparison
Compare BTGO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTGO | ARVN |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | 603 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.3M | 658.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BTGO | ARVN |
|---|---|---|
| Price | $5.40 | $8.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 19 |
| Target Price | $14.83 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 2.3M | 673.6K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.41 | N/A |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.67 | $6.06 |
| 52 Week High | $15.30 | $14.22 |
Technical Indicators
Market Signals| Indicator | BTGO | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 48.13 |
| Support Level | $4.67 | $7.35 |
| Resistance Level | $12.11 | $10.18 |
| Average True Range (ATR) | 0.59 | 0.40 |
| MACD | 0.20 | 0.14 |
| Stochastic Oscillator | 37.05 | 99.57 |
Price Performance
Historical ComparisonAbout BTGO BitGo Holdings Inc. Class A Common Stock
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
About ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.